CP and COVID-19: Along with this finding, a retrospective study of 341 hospitalized patients with COVID-19 treated with high anti-S receptor binding domain antibodies CP matched with a control group that did not receive CP found a significant 60-day mortality decrease in those treated with CP if given within 3 days of hospitalization (17).